Morningstar

Morningstar, Inc.

Equity Bottom-Up

Although Zoetis’ strong first-quarter operational results generally met our expectations, foreign currency headwinds were slightly stronger than we’d anticipated. After making slight adjustments to our near-term projections to reflect the stronger dollar, we’re standing behind our fair value estimate. Zoetis continues to reinforce its wide moat in the animal health arena with the addition of diagnostics from Abaxis, and once again, we saw the companion animal segment deliver double-digit revenue…

United States

Zoetis Inc discovers, develops, manufactures and commercializes animal health medicines and vaccines, with a focus on both livestock and companion animals.  The Companies products are sold in North America, Europe, Africa, Asia, Australia and Latin America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00